Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 9, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction.
Material Changes
The only material change disclosed is a transaction involving Mr. R Bondy, who acquired a beneficial interest in 1 Ordinary Share of GlaxoSmithKline plc. The share was purchased under a Personal Equity Plan on October 2, 2006, at a price of GBP 14.18.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a regulatory disclosure of a director's share acquisition in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by Mr. R Bondy following this acquisition to assess total exposure.
- Confirm the current market price of GlaxoSmithKline plc shares relative to the GBP 14.18 purchase price.
- Review subsequent filings for any additional director transactions or changes in beneficial ownership.